An observational study to discover novel biomarkers for nivolumab in patients with advanced gastric cancer (DELIVER trial): JACCRO GC-08

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Oct 2023 Results of SNP discovery based on gene ontology terms analysis from transcriptome sequencing of whole blood RNA to find predictive biomarkers of nivolumab in advanced gastric cancer, presented at the 48th European Society for Medical Oncology Congress.
06 Jun 2023 Results (n=234) of post-hoc exploratory analyses of survival time by tumor response of nivolumab treatment in previously treated advanced gastric cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
10 Feb 2023 Results of blood-based biomarker analysis assessing efficacy of Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab, published in the European Journal of Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com